Fluorothymidine F-18 PET/CT in Predicting Outcome in Participants with Locally Advanced Pancreatic Cancer

Inclusion Criteria

• Patients with histologically confirmed pancreatic adenocarcinoma (resectable, borderline resectable or locally advanced disease at presentation) are eligible for the study
• Patients should not have any type of curative or palliative therapy for pancreatic adenocarcinoma before enrolling in the study and should be candidates for induction chemotherapy
• Patients must be over 18 years old and capable and willing to provide informed consent
• Patients must have measurable disease (by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria)
• Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3 (restricted to ECOG performance status [PS] 0-2 if age > 70 years)
• Patients of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to FLT PET/CT and the optional FDG PET/CT imaging per institution’s standard of care; a female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria; * Has not undergone a hysterectomy or bilateral oophorectomy; or * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)
• Medically stable as judged by patient’s physician
• Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals of similar chemical or biologic composition to FLT or FDG are NOT eligible
• Ability to understand and the willingness to sign a written informed consent
• Patient must be able to lie still for a 20 to 30 minute PET/CT scan

Exclusion Criteria

• Subjects who had prior chemotherapy or radiotherapy for pancreatic adenocarcinoma cannot participate in the study
• Patient must NOT be pregnant or breast-feeding
• Patients have no clinical evidence of distant metastatic disease
• Patients must not weigh more than the maximum weight limit for the table for the PET/CT scanner where the study is being performed (> 200 kg or 440 lbs)